Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Food and Drug Administration commentary on methodological issues in negative symptom trials.

× No keyword cloud information.

3 in total

1. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

Authors: Thomas Laughren; Robert Levin
Journal: Schizophr Bull Date: 2005-08-03 Impact factor: 9.306

2. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Authors: Robert W Buchanan; Miriam Davis; Donald Goff; Michael F Green; Richard S E Keefe; Andrew C Leon; Keith H Nuechterlein; Thomas Laughren; Robert Levin; Ellen Stover; Wayne Fenton; Steve R Marder
Journal: Schizophr Bull Date: 2005-02-16 Impact factor: 9.306

Review 3. Negative symptoms and cognitive deficits: what is the nature of their relationship?

Authors: Philip D Harvey; Danny Koren; Abraham Reichenberg; Christopher R Bowie
Journal: Schizophr Bull Date: 2005-10-12 Impact factor: 9.306

3 in total

11 in total

Review 1. Pharmacological treatment of negative symptoms in schizophrenia.

Authors: Hans-Jürgen Möller; Pal Czobor
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2015-04-21 Impact factor: 5.270

2. Individual difference in prepulse inhibition does not predict spatial learning and memory performance in C57BL/6 mice.

Authors: Daria Peleg-Raibstein; Singer Philipp; Joram Feldon; Benjamin K Yee
Journal: Cogn Affect Behav Neurosci Date: 2015-12 Impact factor: 3.282

Review 3. Anhedonia in depression and schizophrenia: A transdiagnostic challenge.

Authors: Clare Lambert; Susana Da Silva; Amanda K Ceniti; Sakina J Rizvi; George Foussias; Sidney H Kennedy
Journal: CNS Neurosci Ther Date: 2018-04-23 Impact factor: 5.243

4. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Authors: David Walling; Stephen R Marder; John Kane; W Wolfgang Fleischhacker; Richard S E Keefe; David A Hosford; Chris Dvergsten; Anthony C Segreti; Jessica S Beaver; Steven M Toler; John E Jett; Geoffrey C Dunbar
Journal: Schizophr Bull Date: 2015-06-12 Impact factor: 9.306

5. Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates?

Authors: Morris D Bell; Silvia Corbera; Jason K Johannesen; Joanna M Fiszdon; Bruce E Wexler
Journal: Schizophr Bull Date: 2011-10-05 Impact factor: 9.306

Review 6. Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia.

Authors: Jared W Young; Athina Markou
Journal: Schizophr Bull Date: 2015-07-20 Impact factor: 9.306

7. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.

Authors: Robert A Lasser; Bryan Dirks; Henry Nasrallah; Courtney Kirsch; Joseph Gao; Michael L Pucci; Mary A Knesevich; Jean-Pierre Lindenmayer
Journal: Neuropsychopharmacology Date: 2013-05-08 Impact factor: 7.853

Food and Drug Administration commentary on methodological issues in negative symptom trials.